-
Boji Medical Technology Receives NMPA Approval for TBA Clinical Study in Drug-Resistant Tuberculosis
•
China-based Clinical Research Organization (CRO) Boji Medical Technology Co., Ltd. (SHE: 300404) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a clinical study for TBA, a novel treatment for drug-resistant pulmonary tuberculosis. TBA: A New Approach to Combating Drug-Resistant TuberculosisThe Category 1 chemical drug, co-developed…
-
Guangzhou Boji Medical and CapitalBio Pharma Form Joint Venture to Innovate in Traditional Chinese Medicine
•
Guangzhou Boji Medical Biotechnological Co., Ltd, a Clinical Research Organization (CRO) based in China and listed on the Shenzhen Stock Exchange (SHE: 300404), has entered into a strategic partnership with its wholly-owned Traditional Chinese Medicine (TCM) subsidiary and CapitalBio Pharma, a domestic firm, to collaborate on the research and development…
